Saphenous vein graft failure as a Surrogate Endpoint in Clinical Trials: Revision history

20 April 2016

• curprev 12:2512:25, 20 April 2016‎ Sergekorjian talk contribs‎ 30,495 bytes +3‎ No edit summary

30 October 2012

• curprev 16:3216:32, 30 October 2012‎ C Michael Gibson talk contribs‎ 30,492 bytes −3‎ No edit summary

20 August 2012

• curprev 15:5215:52, 20 August 2012‎ WikiBot talk contribs‎ m 30,495 bytes −6‎ Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)

11 November 2010

• curprev 20:2020:20, 11 November 2010‎ C Michael Gibson talk contribs‎ 30,501 bytes −6‎ →‎Pathophysiologic Basis as to Why SVG Failure is Associated with Adverse Outcomes
• curprev 20:1920:19, 11 November 2010‎ C Michael Gibson talk contribs‎ 30,507 bytes +153‎ →‎Association of SVG Failure after Stenting with Clinical Events

9 November 2010

• curprev 19:3419:34, 9 November 2010‎ C Michael Gibson talk contribs‎ 30,354 bytes +97‎ →‎Caveats in the use of SVG Failure as a Surrogate Endpoint
• curprev 19:1719:17, 9 November 2010‎ C Michael Gibson talk contribs‎ 30,257 bytes +565‎ →‎Caveats in the use of SVG Failure as a Surrogate Endpoint
• curprev 18:5718:57, 9 November 2010‎ C Michael Gibson talk contribs‎ 29,692 bytes −718‎ →‎Caveats in the use of SVG Failure as a Surrogate Endpoint
• curprev 18:5118:51, 9 November 2010‎ C Michael Gibson talk contribs‎ 30,410 bytes +10,073‎ →‎Caveats in the use of SVG Failure as a Surrogate Endpoint
• curprev 18:5018:50, 9 November 2010‎ C Michael Gibson talk contribs‎ 20,337 bytes +13‎ →‎Evaluation of a Surrogate Endpoint
• curprev 18:4918:49, 9 November 2010‎ C Michael Gibson talk contribs‎ 20,324 bytes −4‎ →‎Examples of Surrogate Endpoints
• curprev 18:4618:46, 9 November 2010‎ C Michael Gibson talk contribs‎ 20,328 bytes +12‎ →‎Overview
• curprev 18:4218:42, 9 November 2010‎ C Michael Gibson talk contribs‎ 20,316 bytes +1‎ →‎The disadvantage of surrogate endpoints
• curprev 18:4118:41, 9 November 2010‎ C Michael Gibson talk contribs‎ 20,315 bytes 0‎ →‎The advantages of a surrogate endpoint
• curprev 18:4018:40, 9 November 2010‎ C Michael Gibson talk contribs‎ 20,315 bytes +8,086‎ No edit summary
• curprev 18:3618:36, 9 November 2010‎ C Michael Gibson talk contribs‎ 12,229 bytes +12,229‎ New page: {{SI}} {{CMG}} {{EJ}} ==Overview== One issue that arises is the suitability of SVG patency, and SVG narrowing as a surrogate endpoint for clinical events. There are multiple studie...